{{Infobox_gene}}
{{Expand|time=2014-03-16}}
'''細胞程式死亡-配體1'''（{{lang-en|Programmed cell death 1 ligand 1}}，'''PD-L1'''）也稱為'''表面抗原分化簇274'''（'cluster of differentiation 274，CD274）或 '''B7同源體1'''（B7 homolog 1，B7-H1），是人類體內的一種蛋白質，由CD274基因編碼。<ref>{{cite web | title = Entrez Gene: CD274 CD274 molecule| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=29126| accessdate = }}</ref>

PD-L1 是大小為 40kDa 的第一型[[跨膜蛋白|跨膜蛋白]]，據信其在某些特殊情形（例如懷孕、組織移植、自體免疫疾病，以及諸如肝炎等某些疾病）下，[[免疫系統|免疫系統]]的抑制有關。正常情形下免疫系統會對聚集在[[淋巴結|淋巴結]]或[[脾臟|脾臟]]的外來抗原產生反應，促發具抗原特異性的[[细胞毒性T细胞|细胞毒性T细胞]]（CD8+ T细胞）增殖。而細胞程式死亡受體-1（PD-1）與細胞程式死亡-配體1（PD-L1）結合，可以傳導抑制性的信號，減低淋巴結CD8+ T細胞的增生， 而且PD-1還可以藉由調節Bcl-2基因，控制淋巴結中抗原特異性T細胞的聚積。<ref name="pmid15240681">{{cite journal | author = Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL | title = SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation | journal = Journal of Immunology | volume = 173 | issue = 2 | pages = 945–54 |date=July 2004 | pmid = 15240681 | doi = | url = | issn = }}</ref>

目前發現PD-L1表現的增加可能使癌症逃避宿主免疫系統。在來自腎細胞癌患者的196份腫瘤標本進行的分析發現，PD-L1的表現增加與腫瘤侵襲性增加和死亡風險增加4.5倍有關<ref>{{Cite web|title=Faculty of 1000 evaluation for Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.|url=http://dx.doi.org/10.3410/f.1022731.261693|accessdate=2019-12-21|date=2004-12-09|last=Dranoff|first=Glenn|work=F1000 - Post-publication peer review of the biomedical literature}}</ref>。目前許多PD-L1抑製劑正在作為免疫腫瘤療法發展中，並在臨床試驗中顯示出良好的效果<ref>{{Cite journal|title=Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer|url=http://dx.doi.org/10.21873/anticanres.12326|date=2018-01-20|journal=Anticancer Research|issue=2|doi=10.21873/anticanres.12326|volume=38|issn=0250-7005}}</ref>。臨床上可用的例子包括Durvalumab，atezolizumab和avelumab。<ref>{{Cite web|title=American Cancer Society {{!}} Information and Resources about for Cancer: Breast, Colon, Lung, Prostate, Skin|url=https://www.cancer.org/|accessdate=2019-12-21|work=www.cancer.org|language=en|archive-date=2018-08-03|archive-url=https://web.archive.org/web/20180803012402/https://www.cancer.org/|dead-url=no}}</ref>在正常組織中，STAT3和NF-κB等轉錄因子之間的反饋會限制免疫反應，從而保護宿主組織並限制發炎症狀。在癌症中，轉錄因子之間反饋限制的喪失會導致局部PD-L1表達增加，這可能會限制針對PD-L1藥物的全身治療有效性。<ref>{{Cite journal|title=Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode|url=http://dx.doi.org/10.20892/j.issn.2095-3941.2017.0029|last=Spiros|first=A. Vlahopoulos|date=2017|journal=Cancer Biology & Medicine|issue=3|doi=10.20892/j.issn.2095-3941.2017.0029|volume=14|pages=254|issn=2095-3941}}</ref>

[[Image:B7_family_ligands_and_CD28_family_receptors.JPG|275px]]与CD28家族的相互结合关系]]

==參考資料==
{{reflist}}

==外部連結==
* {{MeshName|CD274+protein,+human}}
{{Clusters of differentiation}}
[https://cancerinformation.com.hk/web/2017/03/19/%e5%85%8d%e7%96%ab%e7%99%82%e6%b3%95%ef%b9%95anti-pd1-%e5%92%8canti-pd-l1/ 免疫療法﹕Anti PD1 和Anti PD-L1]